This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Company News for Dec 26, 2025
by Zacks Equity Research
Companies In The News Are: NVDA, NKE, AAPL, DVAX, SNY, INTC.
biotechnology pharmaceuticals retail semiconductor
Top Stock Reports for AbbVie, Coca-Cola & Chevron
by Mark Vickery
ABBV, KO and CVX headline Zacks' top stock reports as analysts flag growth drivers, strategic moves and key headwinds shaping 2025 outlooks.
consumer-staples medical oil-energy pharmaceuticals
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
by Zacks Equity Research
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
pharmaceuticals
PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth
by Kinjel Shah
Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.
pharmaceuticals
Soft Weekly Jobless Claims Data
by Zacks Equity Research
Soft Weekly Jobless Claims Data.
biotechnology business-services pharmaceuticals
NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?
by Kinjel Shah
NVO secures FDA approval for its first oral obesity pill, Wegovy, giving it a first-to-market edge and raising questions about Lilly's next move.
pharmaceuticals
Xmas Eve Jobless Claims: Still Accommodating
by Mark Vickery
Despite today being Christmas Eve and markets closing at 1pm ET, we see new Weekly Jobless Claims numbers ahead of today's opening bell.
earnings pharmaceuticals staffing
Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know
by Sundeep Ganoria
AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.
biotechs medical pharmaceuticals
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
by Zacks Equity Research
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
biotechnology biotechs medical pharmaceuticals vaccines
The Zacks Analyst Blog Highlights Invesco, Johnson & Johnson, NiSource, Bunge Global and Morgan Stanley
by Zacks Equity Research
Invesco leads Zack' list of five high-yield S&P 500 stocks, highlighting dividend strength and steady income potential for 2026.
agriculture finance pharmaceuticals utilities